



Title: Pre-Exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV) Prevention - NCD 210.15

Decision: The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover drugs used for Pre-Exposure Prophylaxis (PrEP) for beneficiaries with risk of HIV infection for the treatment of HIV prophylaxis.

What this means: Medicare benefits now include coverage of drugs used for Pre-Exposure Prophylaxis (PrEP) services if required components for PrEP are met. Requirements are outlined in the National Coverage Determination (see the link below).

Effective: 09/30/2024

For more information, call Customer Service at the phone number on the back of your member ID card.

You can find the announcement at

<https://www.cms.gov/files/document/prep-hiv-prevention.pdf>

H6874_14636_102024_C

U14636 (10/2024)

U50047

Statement of Nondiscrimination

Aspirus Health Plan complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).